Avanir Pharmaceuticals Inc Stock
Equities
US05348P4019
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2014 | Otsuka : Japan's Otsuka to buy Avanir for $3.5 billion ahead of patent cliff | RE |
2014 | NASDAQ OMX : names 14 stocks to test lower fee and rebate programme | RE |
Managers | Title | Age | Since |
---|---|---|---|
Dan Dalton
CMP | Compliance Officer | - | 16-05-31 |
Kelly Parker
IRO | Public Communications Contact | - | 15-05-31 |
Aneta Ferguson
LAW | General Counsel | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Donald Hayden
CHM | Chairman | 68 | - |
Robert McQuade
BRD | Director/Board Member | 67 | - |
Thomas DesRosier
BRD | Director/Board Member | 69 | - |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- Stock